
P R E S S R E L E A S E

STRATEC reports renewed earnings increase

- **Net profit and earnings per share continue to rise**
- **Sales and gross performance stable**
- **Development projects on schedule**

Birkenfeld, March 25, 2003

STRATEC Biomedical Systems AG, listed in the Prime Standard, has seamlessly maintained the outstanding successes seen in the 2001 fiscal year.

According to preliminary unaudited figures, the net profit rose by 28.6% to € 1,111k (previous year: € 864k).

Earnings per share pursuant to IAS 33 showed very pleasing developments and increased by 19.4% to € 0.344 (previous year: € 0.288).

Due to stable sales and gross performance, it was possible to achieve substantial earnings growth. This improvement is primarily attributable to the successful reduction of the materials quota.

STRATEC had 131 employees at the end of the year, including part-time employees (previous year: 120). The new staff was primarily hired to assist with the development and final assembly of the analyzing systems.

In 2002, STRATEC announced the signing of new development agreements with two US American diagnostics manufacturers. Both projects are currently at an advanced stage. No deviations from the budget targets are expected on the basis of the information available today.

...

The preliminary unaudited figures compiled pursuant to IAS for the 2002 fiscal year are as follows:

Key Figures	2002	2001	Change
Gross performance	€ 28,120k	€ 28,136 k	-0.1%
Sales	€ 26,696k	€ 27,387 k	-2.5%
Earnings before interest, tax, depreciation and amortization	€ 2,831k	€ 2,609 k	+ 8.5%
Earnings before interest and tax	€ 1,996k	€ 1,643 k	+ 21.5%
Earnings before tax	€ 1,792k	€ 1,397 k	+ 28.3%
Annual net profit	€ 1,111k	€ 864 k	+ 28.6%
Earnings per share	€ 0.344	€ 0.288	+ 19.4%

The figures provided above for the 2002 fiscal year are preliminary and are still subject to audit and approval of the annual financial statements. The earnings figures compiled in accordance with the German Commercial Code (HGB) are higher than the equivalent IAS figures.

The definitive figures will be announced at the annual financial statements press conference to be held in Stuttgart on April 25, 2003.

The Annual Report for the 2002 fiscal year will be dispatched at the end of April and published on our homepage. It can then also be downloaded.

About STRATEC Biomedical Systems AG

Based on its own patent-protected technologies STRATEC Biomedical Systems AG (<http://www.stratec-biomedical.de>) designs and manufactures fully automated systems for partners in clinical diagnostics and biotechnology. These partners sell the analyzers to laboratories and research institutes worldwide as system solutions together with their reagents. STRATEC is a publicly listed company. Its shares (SIN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

Further information may be obtained from:

STRATEC Biomedical Systems AG
Investor Relations
André Loy
Gewerbestraße 37
75217 Birkenfeld
Tel: +49 (0) 70 82 / 79 16 43
Fax: +49 (0) 70 82 / 79 16 90
E-Mail: ir@stratec-biomedical.de